Haematology - Lymphoma & CLL Trials

A LIST OF OUR EARLY PHASE Haematology (Lymphoma & CLL) TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

ASTX660-03 A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
Local Project Reference:	149376
Principal Investigator:	Dr William Townsend
Drug Class/ Treatment:	Tolinapant (non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP)) Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine alone
Patient Population:	Peripheral T-Cell Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

CO43805 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
Local Project Reference:	149649
Principal Investigator:	Dr WIlliam Townsend
Drug Class/Treatment:	Mosunetuzumab (bispecific CD20-directed CD3 T-cell engager) or Glofitamab (CD20- and CD3- Bispecific Antibody) In Combination with CC-220 (cereblon E3 ligase modulator) + CC-99282 (E3 Ligase Modulator)
Patient Population:	B-Cell Non-Hodgkin Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

ALLCAR19 Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)
Local Project Reference:	16/0530
Principal Investigator:	Dr Claire Roddie
Drug Class/ Treatrment:	CAR T-Cell Therapy Expressing CD19 Chimeric Antigen Receptor (CD19CAR)
Patient Population:	Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) Chronic Lymphocytic Leukaemia (CLL) Small Lymphocytic Lymphoma (SLL) Adults >/=16 years old
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

NAVAL-1 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Local Project Reference:	140945
Principal Investigator:	Dr. Kirit Ardeshna
Drug Class/ Treatrment:	Nanatinostat (Histone Deacetylase Inhibitor) + Valganciclovir (Antiviral Medication)
Patient Population:	Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

PRiZM+ PRiZM+: A phase II platform study of zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma
Local Project Reference:	144707
Principal Investigator:	Dr. Kate Cwynarski
Drug Class/ Treatrment:	Zanubrutinib (Bruton Tyrosine Kinase Inhibitor) Monotherapy and Combination Therapy
Patient Population:	Relapsed and Refractory Primary CNS Lymphoma
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

recruitment on hold

AUTO4-TL1 Phase I/II study - AUTO4 in patients with T cell non-Hodgkin Lymphoma : A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T Cell Treatment Targeting TRBC1, in Patients with Relapsed or Refractory TRBC1 positive selected T Cell Non-Hodgkin Lymphoma.
Local Project Reference:	17/0680
Principal Investigator:	Dr. Kate Cwynarski
Drug Class/ Treatrment:	AUTO4 - CAR T-Cell Therapy Targeting TRBC1
Patient Population:	Relapsed or Refractory TRBC1 positive selected T Cell Non-Hodgkin Lymphoma.
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

Principal Investigator(s):

Dr. william townsend

Consultant Haematologist